Breaking News on Food Safety & Quality Control

Trends > Rapid analysis

News in brief

Funds will help us expand in Asia - Oxford Nanopore

Post a comment

By Joe Whitworth+

Last updated on 16-Dec-2016 at 09:31 GMT2016-12-16T09:31:49Z

Picture: Oxford Nanopore Technologies. MinION
Picture: Oxford Nanopore Technologies. MinION

Oxford Nanopore Technologies has raised £100m ($126m) in funding through a private placement of ordinary shares bringing the total secured to £351m.

The firm will boost production, sales and marketing for products including MinION (portable DNA sequencer), PromethION (high-throughput, on-demand sequencer) and VolTRAX (automated sample/library preparation device).

The company will also continue to invest in existing products and further expand its pipeline, including the mobile-phone compatible SmidgION sequencer.

MinION is a portable, real time, long-read device designed to bring biological analyses to a variety of applications such as disease/pathogen surveillance, environmental monitoring and food chain surveillance.

Commercially available since 2015, it is in use in more than 50 countries enabling applications within the traditional laboratory environment and in the field.

Each consumable flow cell can generate 5-10GB of DNA sequence data and read lengths of hundreds of kb are possible.

Gordon Sanghera, CEO of Oxford Nanopore, said the funds will be used to expand commercial operations across a range of territories, including in Asia.

The active community of scientists using the MinION has shown that there are myriad possibilities for real time, scalable DNA sequencing with nanopore devices.”

The investment round was led by new investor GT Healthcare and existing firm Woodford Investment Management on behalf of clients. Other investors included IP Group.

Alan Au, founder and managing partner of GT Healthcare Capital Partners, said the platform fundamentally changes and shapes the landscape of DNA/single molecule sequencing.

"We are thrilled to collaborate with Oxford Nanopore's management team, with whom we share the same strategic vision; to extend the reach and accessibility of Nanopore-based sequencing solutions into emerging markets,” he said.

“We are confident that GT Healthcare and Oxford Nanopore will work very well collectively to accelerate our expansion in new markets, particularly the Greater China markets."

Post a comment

Comment title *
Your comment *
Your name *
Your email *

We will not publish your email on the site

I agree to Terms and Conditions

These comments have not been moderated. You are encouraged to participate with comments that are relevant to our news stories. You should not post comments that are abusive, threatening, defamatory, misleading or invasive of privacy. For the full terms and conditions for commenting see clause 7 of our Terms and Conditions ‘Participating in Online Communities’. These terms may be updated from time to time, so please read them before posting a comment. Any comment that violates these terms may be removed in its entirety as we do not edit comments. If you wish to complain about a comment please use the "REPORT ABUSE" button or contact the editors.

Key Industry Events


Access all events listing

Our events, Shows & Conferences...